Neurology: The hysolile therapy in patients with dabiga group stroke.

Dabiga group esters (Dabiga group) is a direct clotting enzyme inhibitor that has been shown to prevent stroke in patients with atrial fibrillationIdalu zumas () are a human-derived monoclonal antibody fragment designed to reverse the anticoagulant effect of the Dabiqa groupThe binding force of Idaluzumab and Dabiga group is more than double that of the dabiga group and clotting enzyme and completely reverses the biological activity of the Dabiqa group in a matter of minutesMultiple case reports and small case series reported the venous thrombosis after the Idalu Zuma anti-reversal dabiga groupIn the article published in the article, the clinical improvement rate reported by these patients who received the treatment showed that the effectiveness of thrombolytic therapy was preservedTheir findings, published on New Zealand, were published in the year to evaluate the frequency and use trends of the Idaluzumab anti-reversal dabiga group and to compare it with the national queue of patients with lysobolic patients who did not use Idaluzumab: months of complications, prognosis, and (time to enter the edhydrant)This is an observational cohort study in which all New Zealand patients treated with stroke reperfusion are required to be included in online country registrationsEach hospital records data including the patient's demographics, treatment delays, complications, prognosis, and the use of IdaluzumabA total of patients received thrombosis treatment from year to yearIn patients, Idaluzumab (average age; annual case) was used before the thrombosisDuring the same period of time (months) patients experienced stroke thrombosis treatment in which the case () was first treated with IdaluzumabPatients treated with Idaluzumab for longer periods of time ( )Examples of patients treated with Idaluzumab () other thrombosis patients () ( )There were no significant thrombosis complications in patients treated with IdaluzumabOn the first day the case () died in patients treated with Idaluzumab () and other thrombolytic patients ()The final authors believe that the proportion of patients with thrombolysis used in the national queue increased from year to yearPatients who used idaluzumab compared to patients who were routinely administered were safe from near-ending outcomes similar despite the delayIdaluzumab facilitates thrombolytic therapy in stroke patients taking dabiga